```html

Uric Acid Gout – A Complete Patient Guide

Overview

Gout is a form of inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and soft tissues. The underlying biochemical problem is hyperuricemia—elevated levels of uric acid in the blood. While any joint can be affected, the first attack most often involves the big toe (the “podagra” presentation).

Who it affects: Historically considered a disease of affluent men, gout now affects both sexes and all ages, largely because of lifestyle changes and comorbid conditions. Men are 3–4 times more likely to develop gout than women; however, post‑menopausal women have a risk that approaches that of men.

Prevalence: In the United States, approximately 9.2 million adults (about 4 % of the adult population) have physician‑diagnosed gout, and an additional 20 % have hyperuricemia without clinical gout (CDC, 2022). Global prevalence ranges from 0.1 % in some Asian countries to >2 % in Polynesia and the Pacific Islands (WHO, 2021).

Symptoms

Gout attacks are characteristically sudden, severe, and often unilateral. The symptom pattern may evolve over time as attacks become more frequent or chronic joint damage develops.

Acute gout flare

• Intense joint pain – Often described as “excruciating” or “burning” and peaking within 12–24 hours.
• Swelling and warmth – The affected joint becomes visibly enlarged, red, and feels hot to the touch.
• Rapid onset – Pain frequently begins at night and can awaken the patient.
• Limited range of motion – Movement is painful; the joint may be stiff.
• Tophi formation (later attacks) – Chalky, subcutaneous nodules of urate crystals, most often on the elbows, fingers, ears, or Achilles tendon.

Chronically active gout

• Persistent joint discomfort between attacks.
• Joint deformity and decreased function due to cartilage erosion.
• Kidney stones (uric acid stones) causing flank pain or hematuria.

Causes and Risk Factors

Uric acid is the end product of purine metabolism. When production exceeds renal excretion, serum urate rises above the solubility threshold (≈6.8 mg/dL), allowing crystal formation.

Primary causes

• Genetic predisposition – Certain HLA‑B*58:01 and SLC2A9 gene variants reduce uric acid clearance.
• Overproduction of uric acid – High‑purine diets (red meat, organ meats, seafood), increased cell turnover (psoriasis, hemolysis, chemotherapy).
• Decreased renal excretion – Chronic kidney disease, use of diuretics, low‑dose aspirin, or certain antihypertensives.

Important risk factors

• Male sex (especially 30–60 years)
• Obesity (BMI ≥ 30 kg/m²) – each 5‑unit increase raises gout risk ~2‑fold
• Metabolic syndrome: hypertension, hyperlipidemia, insulin resistance
• Alcohol intake, particularly beer and spirits
• Fructose‑rich beverages (soda, fruit drinks)
• Lead exposure (occupational or environmental)
• Use of certain medications: loop/thiazide diuretics, low‑dose aspirin, cyclosporine, tacrolimus
• Family history of gout or hyperuricemia

Diagnosis

Diagnosing gout requires a combination of clinical assessment, laboratory testing, and occasionally imaging.

Clinical criteria

• Sudden onset of monoarticular arthritis with typical distribution (first MTP joint, ankle, knee, elbow).
• Presence of tophi or previous documented attacks.

Laboratory tests

• Serum urate level – A level > 7 mg/dL supports gout but may be normal during an acute flare.
• Joint aspiration (arthrocentesis) – Gold standard. Fluid is examined under polarized light microscopy for negatively birefringent, needle‑shaped MSU crystals.
• Complete blood count & C‑reactive protein (CRP) – help gauge inflammation.

Imaging

• Ultrasound – Shows the “double contour” sign (urate deposition on cartilage) and tophus aggregates.
• Dual‑energy CT (DECT) – Differentiates urate crystals from calcium, useful when aspiration is not feasible.
• Standard X‑ray – May reveal erosions with overhanging edges in chronic gout.

Treatment Options

Management aims to (1) relieve acute pain, (2) prevent future flares, and (3) lower serum urate long‑term to dissolve crystals.

Acute‑attack therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Indomethacin 50 mg PO q6h, naproxen 500 mg PO q12h. Contraindicated in renal failure or peptic ulcer disease.
• Colchicine – Loading dose 1.2 mg PO, then 0.6 mg 1 hour later; maintenance 0.6 mg PO once or twice daily (dose adjusted for renal function).
• Corticosteroids – Prednisone 30–40 mg PO daily taper over 1‑2 weeks, or intra‑articular methylprednisolone for a single joint.

Long‑term urate‑lowering therapy (ULT)

Initiated after the first attack in patients with risk factors, or after ≥2 attacks, or when tophi or kidney stones are present.

• Allopurinol – Start 100 mg PO daily; increase by 100 mg every 2‑4 weeks to target serum urate < 6 mg/dL (< 5 mg/dL if tophi). Watch for hypersensitivity syndrome, especially in HLA‑B*58:01 carriers.
• Febuxostat – 40 mg PO daily, titrated to 80 mg; an alternative for allopurinol‑intolerant patients. Cardiovascular safety considerations per FDA warnings.
• Probenecid – 250 mg PO BID; enhances renal urate excretion; useful when renal function is preserved.
• Lesinurad – 200 mg PO daily combined with a xanthine oxidase inhibitor; approved for patients with inadequate response to allopurinol/febuxostat.
• Uricase agents (pegloticase, rasburicase) – Intravenous recombinant uricase for refractory gout with tophi; monitor for infusion reactions.

Lifestyle and adjunct measures

• Limit purine‑rich foods: red meat, organ meats, shellfish.
• Reduce alcohol, especially beer and spirits.
• Restrict fructose‑sweetened beverages.
• Maintain healthy body weight (5‑10 % loss can lower urate by 0.5–1 mg/dL).
• Stay well‑hydrated (≥2–3 L water/day) to facilitate renal uric acid clearance.
• Consider low‑fat dairy (milk, yogurt) which may lower urate.

Living with Uric Acid Gout

Successful long‑term control is a partnership between you and your healthcare team.

• Medication adherence – Take ULT daily even if you feel well; missing doses raises the risk of flares.
• Regular monitoring – Serum urate checks every 2–4 weeks after starting or adjusting ULT, then every 3–6 months once stable.
• Track attacks – Keep a diary of joint pain, diet, alcohol intake, and medication use to identify triggers.
• Foot care – Inspect toes daily for tophi or skin breakdown; wear comfortable shoes with good arch support.
• Exercise safely – Low‑impact activities (walking, swimming, cycling) improve cardiovascular health without overstressing joints.
• Manage comorbidities – Treat hypertension, diabetes, and hyperlipidemia aggressively; these conditions share pathways with hyperuricemia.

Prevention

Even before a first gout attack, adopting preventive habits can keep uric acid levels in check.

• Eat a balanced diet – Emphasize vegetables, whole grains, legumes, low‑fat dairy, and plant‑based proteins.
• Control weight – Aim for a BMI < 25 kg/m²; gradual weight loss (0.5 kg/week) is safest.
• Limit alcohol – No more than 1 standard drink/day for women, 2 for men; avoid binge drinking.
• Stay hydrated – Urine should be pale yellow; avoid sugary drinks.
• Review medications – Ask your doctor whether a diuretic or low‑dose aspirin can be replaced or dose‑adjusted.
• Screen high‑risk individuals – People with a family history, obesity, or metabolic syndrome benefit from periodic serum urate testing.

Complications

If left untreated, gout can progress beyond painful flares.

• Joint destruction – Chronic inflammation erodes cartilage and bone, leading to permanent arthropathy.
• Tophi – Large urate deposits may ulcerate, become infected, or impair function (e.g., hand grip, gait).
• Kidney disease – Uric acid stones, interstitial nephritis, and accelerated decline in renal function.
• Cardiovascular events – Hyperuricemia is an independent risk factor for hypertension, coronary artery disease, and stroke (NIH, 2023).
• Psychosocial impact – Recurrent pain can limit activity, lead to depression, and affect work productivity.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Prevalence of Arthritis and Other Rheumatic Conditions — United States, 2022.” CDC.gov.
• World Health Organization. “Gout and Hyperuricemia.” WHO Fact Sheet, 2021. who.int.
• Mayo Clinic. “Gout.” Updated 2023. mayoclinic.org.
• Cleveland Clinic. “Gout Treatment Options.” 2024. clevelandclinic.org.
• National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Gout.” 2023. NIAMS.
• Dalbeth N, et al. “2023 American College of Rheumatology Guideline for the Management of Gout.” *Arthritis Care & Research*. 2023;75(5):645‑659.

```